New York, New York 3/19/2010 11:15:00 PM
News / Business

CVS Caremark (NYSE: CVS) CEO Salary Drops 17 Percent

CVS Caremark Corp. (NYSE: CVS) chief executive Thomas Ryan received compensation valued at $14.4 million in 2009, down 17 percent the $17.4 million he received the previous year, according to Associated Press.

 

Ryan, who serves as president, CEO and chairman, saw a decline largely due to a decrease in his performance-based cash bonus and stock-based awards, according to an Associated Press calculation of figures disclosed in a regulatory filing.

 

Xplosive Stocks, an online financial publication, provides investors timely stock market information.

Sign Up Today for our Free Stock Newsletter

 

Ryan earned $1.4 million in salary in 2009, the same as in 2008. He also received stock and options valued at $9.3 million on the days they were granted, down 23 percent from similar awards of $11 million in 2008.

 

Ryan also received a $3.5 million performance-based cash bonus, compared with a $4.6 million bonus the year before.

 

Ryan received $269,000 in perks, down from $466,000 in 2008. His perks included company contributions to defined contribution plans, use of the company aircraft, home security and other items.

 

The drugstore chain's profit grew 16 percent in 2009 to $3.7 billion, or $2.55 per share. Revenue rose 13 percent to $98.73 billion, compared to $87.47 billion. Shares of the company rose 12 percent during the year.

 

Sign up for the free Xplosive Stocks newsletter. Investors interested in receiving small cap stock alerts through the penny stock newsletter published by Xplosive Stocks can sign up for free by visiting our website.

 

About Us

 

Xplosive Stock is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We focus on Xplosive Stocks and track small cap companies that are on the brink of a financial breakout. To feature a company on our website please contact us at the email listed below.

 

Please click here to read the full disclaimer.